Hangzhou Alltest Biotech Co., Ltd.

Equities

688606

CNE1000053G6

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
56.63 ^CNY	-0.65%		-2.04%	-17.45%

Apr. 29	China, HK stocks rise, led by property shares	RE
Apr. 26	Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.

February 23, 2024

From January 1, 2024 to February 23, 2024, the company has repurchased 630,000 shares, representing 0.81% for CNY 36.93 million. With this, the company has completed the repurchase of 1,030,000 shares, representing 1.32% for CNY 59.58 million under the buyback announced on August 17, 2023.

Latest news about Hangzhou Alltest Biotech Co., Ltd.

China, HK stocks rise, led by property shares	Apr. 29	RE
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.	Feb. 23	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback announced on August 17, 2023, has closed with 1,030,000 shares, representing 1.32% for CNY 59.58 million.	Feb. 22	CI
Hangzhou Alltest Biotech Co., Ltd. agreed to acquire an unknown stake in Hangzhou Weisibo Medical Technology Co., Ltd.	Jan. 05	CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.	Jan. 02	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.	23-10-10	CI
Hangzhou Alltest Biotech Co., Ltd.(XSSC:688606) added to S&P Global BMI Index	23-09-18	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Hangzhou Alltest Biotech Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	23-08-16	CI
Hangzhou Alltest Biotech Co., Ltd. authorizes a Buyback Plan.	23-08-15	CI
Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback announced on July 22, 2022, has expired.	23-07-20	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Hangzhou Tongzhou Biotechnology Co., Ltd. announced that it expects to receive CNY 19 million in funding from Hangzhou Alltest Biotech Co., Ltd.	23-01-08	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Atomo Diagnostics Limited Signs Agreement with Hangzhou Alltest Biotech Co., Ltd, for Supply of A Covid-19 1 Rapid Antigen Self-Test in the Australian and New Zealand Markets	22-08-22	CI
Hangzhou Alltest Biotech Co., Ltd. announces an Equity Buyback for CNY 115.5 million worth of its shares.	22-07-22	CI
Hangzhou Alltest Biotech Co., Ltd. authorizes a Buyback Plan.	22-07-21	CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Hangzhou Alltest Biotech Co., Ltd.(SHSE:688606) added to Shanghai Stock Exchange Composite Index	22-03-25	CI
Hangzhou Alltest Biotech Co., Ltd.(SHSE:688606) added to Shanghai Stock Exchange A Share Index	22-03-24	CI

Chart Hangzhou Alltest Biotech Co., Ltd.

Duration

Period

Chart Hangzhou Alltest Biotech Co., Ltd.

More charts

Company Profile

Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Companyâs main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, womenâs health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HANGZHOU ALLTEST BIOTECH CO., LTD.	-17.45%	610M
BIOMÉRIEUX	-6.41%	12.2B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.07%	8.22B
DIASORIN S.P.A.	+5.77%	5.72B
LANTHEUS HOLDINGS, INC.	+28.13%	5.42B
10X GENOMICS, INC.	-59.44%	2.7B
ANDON HEALTH CO., LTD.	+8.04%	2.63B
VITROLIFE AB	-6.47%	2.38B
MYRIAD GENETICS, INC.	+21.84%	2.1B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.15%	1.81B

Diagnostic & Testing Substances